AR032318A1 - Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa - Google Patents

Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Info

Publication number
AR032318A1
AR032318A1 ARP010101735A ARP010101735A AR032318A1 AR 032318 A1 AR032318 A1 AR 032318A1 AR P010101735 A ARP010101735 A AR P010101735A AR P010101735 A ARP010101735 A AR P010101735A AR 032318 A1 AR032318 A1 AR 032318A1
Authority
AR
Argentina
Prior art keywords
halo
disease
useful
ischemia
amino
Prior art date
Application number
ARP010101735A
Other languages
English (en)
Inventor
Margaret L Grapperhaus
James A Sikorski
Alok Awasthi
Jane Wang
Barnett S Pitzele
Donald W Hansen Jr
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR032318A1 publication Critical patent/AR032318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto derivado halogenado del ácido 2-amino-5,6 heptenoico de formula (1), o una sal aceptable para uso farmacéutico del mismo, donde R1 se selecciona del grupo formado por hidrogeno, halo y alquilo que puede ser opcionalmente sustituido por uno o más halo; R2 se selecciona del grupo formado por hidrogeno, halo y alquilo que puede ser opcionalmente sustituido por uno o más halo; y con la condicion de que al menos uno entre R1 o R2 contenga un halo. Se describe la composicion farmacéutica que lo comprende y el uso de dichos compuestos y composiciones en la fabricacion de medicamentos utiles como inhibidores de la Oxido Nítrico Sintetasa. Otras condiciones en las cuales puede ser util la inhibicion del ON incluyen la enfermedad inflamatoria del intestino, la isquemia cardiovascular, la diabetes, la deficiencia cardíaca congestiva, la miocarditis, la arteriosclerosis, la migrana, el glaucoma, el aneurisma aortico, la esofagitis por reflujo, la diarrea, el síndrome del colon irritable, la fibrosis quística, el enfisema, el asma, la bronquieclasis, la hiperalgesia (alodinia), la isquemia cerebral (isquemia focal, ataque trombotico e isquemia global (secundaria a la detencion del corazon)), la esclerosis multiple y otras afecciones del sistema nervioso central mediadas por el ON, por ejemplo, el mal de Parkinson y la enfermedad de Alzheimer. Otras afecciones neurodegenerativas sobre las cuales puede ser util la inhibicion del ON incluyen la degeneracion nerviosa y/o la necrosis nerviosas en trastornos tales como, por ej., la hipoxia, la hipoglucemia, la epilepsia, y en lesiones externas (como por ej., en la médula espinal y en la cabeza), las convulsiones hiperbáricas y la toxicidad por oxígeno, la demencia, por ej. la demencia pre-senil y la demencia relacionada con el SIDA, la corea de Sydenham, la enfermedad de Hunlington, la Esclerosis Lateral Amiotrofica, la enfermedad de Korsakoff, la imbecilidad relacionada con una afeccion en los vasos cerebrales, trastornos del sueno, esquizofrenia, depresion u otros síntomas asociados con el Síndrome Premestrual (PMS), ansiedad y ataque séptico. La inhibicion del oxido nítrico puede tener una funcion también en el tratamiento del dolor, incluyendo dolores somatogénicos (nocioceptivos o neuropáticos), tanto agudos como cronicos. Podría usarse un inhibidor del oxido nítrico en cualquier situacion en la cual se pudiera administrarse un NSAID comun o un analgésico opiáceo. Además, otras afecciones que pueden tratarse inhibiendo la produccion de ON incluyen la tolerancia a los opiáceos en pacientes que necesitan de analgésicos opiáceos de uso prolongado y la tolerancia a la benzodiazepinas en pacientes que toman benzodiazepinas, y otros comportamientos adictivos, por ej. nicotina y trastornos de la alimentacion. Los agentes que inhiben el ON pueden ser utiles también como agentes antibacterianos.
ARP010101735A 2000-04-13 2001-04-11 Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa AR032318A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19703200P 2000-04-13 2000-04-13

Publications (1)

Publication Number Publication Date
AR032318A1 true AR032318A1 (es) 2003-11-05

Family

ID=22727736

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101735A AR032318A1 (es) 2000-04-13 2001-04-11 Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Country Status (14)

Country Link
US (1) US6465686B2 (es)
EP (1) EP1282413A4 (es)
JP (1) JP2003530435A (es)
KR (1) KR20030040202A (es)
CN (1) CN1437468A (es)
AR (1) AR032318A1 (es)
AU (1) AU2001255391A1 (es)
BR (1) BR0110143A (es)
CA (1) CA2405597A1 (es)
EA (1) EA200201054A1 (es)
MX (1) MXPA02010068A (es)
NZ (1) NZ521879A (es)
WO (1) WO2001078719A1 (es)
ZA (1) ZA200208169B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
JPWO2003022309A1 (ja) * 2001-09-10 2004-12-24 小野薬品工業株式会社 アレルギー疾患治療剤
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
MXPA04011335A (es) * 2002-05-16 2005-07-01 Pharmacia Corp Metodos para el tratamiento de enfermedades y afecciones respiratorias con un inhibidor selectivo de inos y un inhibidor de pde y composiciones para esto.
EP1506040A2 (en) * 2002-05-16 2005-02-16 Pharmacia Corporation Selective inos inhibitors for the treatment of respiratory diseases and conditions
DK1645558T3 (da) * 2002-06-19 2008-10-06 Biovitrum Ab Publ Piperazinylpyraziner som serotonin 5-HT2C receptormodulatorer
CN1674885A (zh) * 2002-08-02 2005-09-28 法玛西雅公司 治疗和预防胃肠病症的方法
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US20050203082A1 (en) * 2003-08-13 2005-09-15 Hsu Chung Y. Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DK2180787T3 (da) 2007-08-01 2014-02-03 Univ Pittsburgh Nitrooliesyremodulering af type ii-diabetes
WO2009134383A2 (en) 2008-05-01 2009-11-05 Complexa Inc. Vinyl substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8686038B2 (en) 2008-06-19 2014-04-01 The Univsersity of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
EP2322514A1 (en) * 2009-11-11 2011-05-18 Bayer Schering Pharma Aktiengesellschaft Homoglutamic acid and glutamic acid derivatives
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
IL297844A (en) 2015-10-02 2023-01-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
EP3801526B1 (en) 2018-05-25 2023-12-27 Imara Inc. Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-one
CN109021061B (zh) * 2018-09-29 2019-07-12 郭可点 雷公藤甲素靶向前药及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
AU5533094A (en) 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
EP0724435B1 (en) 1993-10-21 2002-08-14 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
JPH09504028A (ja) 1993-10-21 1997-04-22 ジー．ディー．サール アンド カンパニー 酸化窒素シンターゼ抑制剤として有用なアミジノ誘導体
ATE195933T1 (de) * 1994-03-10 2000-09-15 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
ES2141347T3 (es) * 1994-03-24 2000-03-16 Searle & Co Amidino-derivados utiles como inhibidores de oxido nitrico sintasa.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
EP0821674B1 (en) 1995-04-20 2003-08-06 G.D. SEARLE & CO. Cyclic amidino agents useful as nitric oxide synthase inhibitors
AU712995B2 (en) 1995-05-10 1999-11-18 G.D. Searle & Co. Nitric oxide synthase inhibitors derived from cyclic amidines
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US5830917A (en) 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
GEP20043179B (en) * 1998-03-11 2004-02-25 Searle & Co Halogenated Amidino Amino Acid Derivatives Useful as Nitric Oxide Synthase Inhibitors
AR030741A1 (es) * 2000-09-15 2003-09-03 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa

Also Published As

Publication number Publication date
US6465686B2 (en) 2002-10-15
CA2405597A1 (en) 2001-10-25
AU2001255391A1 (en) 2001-10-30
WO2001078719A1 (en) 2001-10-25
NZ521879A (en) 2004-12-24
ZA200208169B (en) 2003-10-10
EP1282413A4 (en) 2004-12-01
BR0110143A (pt) 2005-01-11
KR20030040202A (ko) 2003-05-22
CN1437468A (zh) 2003-08-20
JP2003530435A (ja) 2003-10-14
EP1282413A1 (en) 2003-02-12
MXPA02010068A (es) 2003-09-10
US20020049202A1 (en) 2002-04-25
EA200201054A1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
AR032318A1 (es) Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
EP3129023B1 (en) Potent soluble epoxide hydrolase inhibitors
WO2007110627A3 (en) 3,7-diamino-10h-phenothiazine salts and their use
WO2005121130A3 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2004083167A1 (ja) スルファミド誘導体及びその医薬組成物
JP2012502946A (ja) 細菌感染症処置に適用するための有機化合物
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
JPH07504654A (ja) オキソ及びヒドロキシ置換炭化水素のアミン誘導体
WO2004085433A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
JP7085686B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物およびそれを含む薬剤学的組成物
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
WO2003070731A3 (en) Azabicyclic compounds for the treatment of disease
AU2005235248A1 (en) Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists
US20140371228A1 (en) Novel therapeutic agents
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
DE3610643A1 (de) Neue phenoxyalkylcarbonsaeure-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
EP3400222B1 (en) Zwitterionic propargyl-linked antifolates useful for treating bacterial infections
TN2009000205A1 (fr) Analogues de pyrazoles
EP3901150A1 (en) Application of monocyclic beta-lactam compound in pharmacy
KR102418562B1 (ko) 설폰아마이드 유도체 화합물 및 이의 우레아제 억제제로서의 용도
WO2004069197A3 (en) Novel substituted 2,3-benzodiazepine derivatives
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
US20100069364A1 (en) Substituted pyrazoline compounds with acat inhibition activity, their preparation and use as medicaments
ID24231A (id) Derivat-derivat 5-disubstitusi-1,2,4-tiadiazolil yang menghambat angiogenesis

Legal Events

Date Code Title Description
FB Suspension of granting procedure